Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care

AIM: To assess if sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) reduce the risk of all‐cause mortality, cardiovascular death and hospitalization for heart failure (HF) or chronic kidney disease (CKD) to a greater extent than dipeptidyl peptidase‐4 inhibitors (DPP4is) in people with type 2 dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Idris, Iskandar, Zhang, Ruiqi, Mamza, Jil Billy, Ford, Mike, Morris, Tamsin, Banerjee, Amitava, Khunti, Kamlesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518855/
https://www.ncbi.nlm.nih.gov/pubmed/33973690
http://dx.doi.org/10.1111/dom.14437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518855/
https://www.ncbi.nlm.nih.gov/pubmed/33973690
http://dx.doi.org/10.1111/dom.14437

Ejemplares similares